Precise identification of patients at highest risk for developing Cytomegalovirus (CMV) DNAemia may improve CMV infection management in the allogeneic hematopoietic stem cell transplantation (allo-HSCT) setting. Here, we studied the potential use of detecting free CMV micro(mi)RNAs circulating in plasma for predicting CMV DNAemia in this clinical scenario. A total of 62 adult allo-HSCT recipients were included in this prospective observational multicenter study. Plasma CMV DNA load was monitored using the CMV RealTime CMV PCR (Abbott Molecular, Des Plaines, IL, USA). Detection of mature CMV miRNAs in plasma drawn by days + 7, + 14 and + 30 after allo-HSCT was performed using the miScript PCR System (Qiagen, Hilden, Germany). Assays could be optimized for five out of the seven targeted CMV miRNAs: UL36-5p, US33-5p, UL148D, UL22A-5p and UL112-3p. Of the 62 patients included in the study, 42 developed a first episode of CMV DNAemia at a median of 35 days after allo-HSCT. All targeted CMV miRNA were detected early after transplantation, with CMV miRNA US33-5p and UL112-3p the most commonly found species at any time point; nevertheless, neither the detection rate of CMV miRNAs nor their abundance allowed discrimination between patients with subsequent CMV DNAemia and those with no CMV DNAemia. The data presented herein do not support any predictive utility of these CMV miRNAs for first episodes of CMV DNAemia in a cohort consisting primarily of allo-HSCT patients receiving haploidentical allografts.

中文翻译：

---

血浆巨细胞病毒（CMV）microRNA检测在异基因造血干细胞移植受者中预测CMV DNAemia的实用性研究。

精确鉴定罹患巨细胞病毒风险最高的患者（CMV）DNAemia可以改善同种异体造血干细胞移植（allo-HSCT）环境中的CMV感染管理。在这里，我们研究了检测血浆中游离的CMV micro（mi）RNA在这种临床情况下预测CMV DNAemia的潜在用途。这项前瞻性观察性多中心研究共纳入了62位成年异体HSCT成人。使用CMV RealTime CMV PCR（Abbott Molecular，Des Plaines，IL，USA）监测血浆CMV DNA负载。使用miScript PCR系统（Qiagen，Hilden，德国），在all-HSCT后第+ 7，+ 14和+30天抽取血浆中成熟的CMV miRNA。可以针对七个靶向CMV miRNA中的五个优化检测：UL36-5p，US33-5p，UL148D，UL22A-5p和UL112-3p。在研究中包括的62名患者中，42例在异基因造血干细胞移植后的中位35天出现了CMV DNA血症的首发。移植后早期就检测到所有靶向的CMV miRNA，其中CMV miRNA US33-5p和UL112-3p在任何时间点都是最常见的物种。但是，CMV miRNA的检出率及其丰度都不能区分随后的CMV DNAemia患者和没有CMV DNAemia的患者。本文提供的数据不支持这些CMV miRNA在主要由接受单倍同种异体移植的同种HSCT患者组成的队列中对CMV DNAemia首次发作的任何预测效用。CMV miRNA的检出率及其丰度均不能区分随后的CMV DNAemia和无CMV DNAemia的患者。本文提供的数据不支持这些CMV miRNA在主要由接受单倍同种异体移植的同种HSCT患者组成的队列中对CMV DNAemia首次发作的任何预测效用。CMV miRNA的检出率及其丰度均不能区分随后的CMV DNAemia和无CMV DNAemia的患者。本文提供的数据不支持这些CMV miRNA在主要由接受单倍同种异体移植的同种HSCT患者组成的队列中对CMV DNAemia首次发作的任何预测效用。